U.S. markets closed

  • S&P 500

    4,330.00
    -72.20 (-1.64%)
     

  • Dow Jones

    34,070.42
    -370.46 (-1.08%)
     

  • Nasdaq

    13,223.99
    -245.14 (-1.82%)
     

  • Russell 2000

    1,781.83
    -28.28 (-1.56%)
     

  • Petróleo

    89.74
    +0.11 (+0.12%)
     

  • Oro

    1,940.20
    +0.60 (+0.03%)
     

  • Plata

    23.69
    +0.01 (+0.03%)
     

  • dólar/euro

    1.0663
    +0.0001 (+0.01%)
     

  • Bono a 10 años

    4.4800
    +0.1310 (+3.01%)
     

  • dólar/libra

    1.2292
    -0.0002 (-0.02%)
     

  • yen/dólar

    147.6410
    +0.0780 (+0.05%)
     

  • Bitcoin USD

    26,573.86
    -580.62 (-2.14%)
     

  • CMC Crypto 200

    566.31
    -9.95 (-1.73%)
     

  • FTSE 100

    7,678.62
    -53.03 (-0.69%)
     

  • Nikkei 225

    32,571.03
    -452.75 (-1.37%)
     

2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip

Prosper Junior Bakiny, The Motley Fool
·4  min de lectura
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip

Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least 50 consecutive years to become a member of this elite group. Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns.

Continuar leyendo